Clinical trial results:
A phase 3, double-blind, multicenter, randomized, placebo-controlled study to assess the efficacy and safety of SPL7013 Gel (VivaGel®) for the treatment of bacterial vaginosis

Summary

EudraCT number	2012-000752-33
Trial protocol	DE BE
Global end of trial date	05 October 2012

Results information

Result version number	v1 (current)
This version publication date	16 December 2021
First version publication date	16 December 2021

Trial information

Trial identification

Sponsor protocol code	SPL7013-016

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01577537
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Starpharma Pty Ltd
Sponsor organisation address	4-6 Southampton Crescent, Abbotsford, Australia, 3067
Public contact	VP Development and Regulatory Affairs, Starpharma Pty Ltd, 0061 385322700, jeremy.paull@starpharma.com
Scientific contact	VP Development and Regulatory Affairs, Starpharma Pty Ltd, 0061 385322700, jeremy.paull@starpharma.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	28 November 2012
Is this the analysis of the primary completion data?	Yes
Primary completion date	05 October 2012
Global end of trial reached?	Yes
Global end of trial date	05 October 2012
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the efficacy of 1% SPL7013 Gel compared with placebo gel for the treatment of bacterial vaginosis (BV)

Protection of trial subjects:

The study was conducted in accordance with Good Clinical Practice (GCP) as required by the International Council for Harmonisation guidelines and in accordance with country-specific laws and regulations governing clinical studies of investigational products (IPs). Compliance with these requirements also constitutes conformity with the ethical principles of the Declaration of Helsinki. An informed consent document approved by each study centre's IRB/IEC was signed by the subject or legal representative and the investigator before any study-related procedures were performed. The investigator provided copies of the signed informed consent to the subject or legal representative, and the original was retained by the investigator.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	24 March 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 21
Country: Number of subjects enrolled	Germany: 59
Country: Number of subjects enrolled	United States: 171
Worldwide total number of subjects	251
EEA total number of subjects	80

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0

Adolescents (12-17 years)	0
Adults (18-64 years)	250
From 65 to 84 years	0
85 years and over	1

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Post-menarchal females, aged 12 years or more, with current BV (4/4 Amsel criteria and Nugent score 4-10), otherwise healthy, as determined by medical history, physical examination, and normal Pap smear at, or documented within 24 months of, screening.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	1% SPL7013 Gel

Arm description: -

Arm type	Experimental
Investigational medicinal product name	1% SPL7013 Gel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Gel
Routes of administration	Vaginal use

Dosage and administration details:

5 g once daily for 7 days

Arm title	Placebo

Arm description: -

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Gel
Routes of administration	Vaginal use

Dosage and administration details:

5 g once daily for 7 days

Number of subjects in period 1	1% SPL7013 Gel	Placebo
Started	128	123
Completed	120	116
Not completed	8	7
Consent withdrawn by subject	3	2
Pregnancy	1	-

Lost to follow-up	3	4
Scheduling difficulty	1	1

Baseline characteristics

Reporting groups	
Reporting group title	1% SPL7013 Gel
Reporting group description: -	
Reporting group title	Placebo
Reporting group description: -	

Reporting group values	1% SPL7013 Gel	Placebo	Total
Number of subjects	128	123	251
Age categorical Units: Subjects			
In utero			0
Preterm newborn infants (gestational age < 37 wks)			0
Newborns (0-27 days)			0
Infants and toddlers (28 days-23 months)			0
Children (2-11 years)			0
Adolescents (12-17 years)			0
Adults (18-64 years)			0
From 65-84 years			0
85 years and over			0
Age continuous Units: years			
arithmetic mean	35	36.3	
standard deviation	± 10	± 12.1	-
Gender categorical Units: Subjects			
Female	128	123	251
Male	0	0	0

Subject analysis sets	
Subject analysis set title	SPL7013 Gel mITT
Subject analysis set type	Modified intention-to-treat

Subject analysis set description:

All randomized participants who received (were dispensed) the study medication, excluding any participants who returned all the study medication unused, and whose whose vaginal fluid sample at baseline was determined to have a Nugent score of 4 or higher.

Subject analysis set title	Placebo mITT
Subject analysis set type	Modified intention-to-treat

Subject analysis set description:

All randomized participants who received (were dispensed) the study medication, excluding any participants who returned all the study medication unused and whose vaginal fluid sample at baseline was determined to have a Nugent score of 4 or higher.

Subject analysis set title	SPL7013 Safety
Subject analysis set type	Safety analysis

Subject analysis set description:

All randomized participants who received (were dispensed) the study medication, excluding any participants who returned all the study medication unused.

Subject analysis set title	Placebo Safety
Subject analysis set type	Safety analysis

Subject analysis set description:

All randomized participants who received (were dispensed) the study medication, excluding any participants who returned all the study medication unused.

Reporting group values	SPL7013 Gel mITT	Placebo mITT	SPL7013 Safety
Number of subjects	120	117	126
Age categorical			
Units: Subjects			
In utero			
Preterm newborn infants (gestational age < 37 wks)			
Newborns (0-27 days)			
Infants and toddlers (28 days-23 months)			
Children (2-11 years)			
Adolescents (12-17 years)			
Adults (18-64 years)			
From 65-84 years			
85 years and over			
Age continuous			
Units: years			
arithmetic mean	34.9	36.2	35
standard deviation	± 9.9	± 12.3	± 10
Gender categorical			
Units: Subjects			
Female	120	117	126
Male	0	0	0

Reporting group values	Placebo Safety		
Number of subjects	123		
Age categorical			
Units: Subjects			
In utero			
Preterm newborn infants (gestational age < 37 wks)			
Newborns (0-27 days)			
Infants and toddlers (28 days-23 months)			
Children (2-11 years)			
Adolescents (12-17 years)			
Adults (18-64 years)			
From 65-84 years			
85 years and over			
Age continuous			
Units: years			
arithmetic mean	36.3		
standard deviation	± 12.1		
Gender categorical			
Units: Subjects			
Female	123		
Male	0		

End points

End points reporting groups

Reporting group title	1% SPL7013 Gel
Reporting group description: -	
Reporting group title	Placebo
Reporting group description: -	
Subject analysis set title	SPL7013 Gel mITT
Subject analysis set type	Modified intention-to-treat
Subject analysis set description:	
All randomized participants who received (were dispensed) the study medication, excluding any participants who returned all the study medication unused, and whose whose vaginal fluid sample at baseline was determined to have a Nugent score of 4 or higher.	
Subject analysis set title	Placebo mITT
Subject analysis set type	Modified intention-to-treat
Subject analysis set description:	
All randomized participants who received (were dispensed) the study medication, excluding any participants who returned all the study medication unused and whose vaginal fluid sample at baseline was determined to have a Nugent score of 4 or higher.	
Subject analysis set title	SPL7013 Safety
Subject analysis set type	Safety analysis
Subject analysis set description:	
All randomized participants who received (were dispensed) the study medication, excluding any participants who returned all the study medication unused.	
Subject analysis set title	Placebo Safety
Subject analysis set type	Safety analysis
Subject analysis set description:	
All randomized participants who received (were dispensed) the study medication, excluding any participants who returned all the study medication unused.	

Primary: Number of Women With Clinical Cure at the End of Treatment Visit (EOT)

End point title	Number of Women With Clinical Cure at the End of Treatment Visit (EOT)
End point description:	
Clinical Cure is defined as the resolution of clinical findings (ie Amsel criteria) from the Baseline visit (Day 1)	
End point type	Primary
End point timeframe:	
Day 9-12	

End point values	SPL7013 Gel mITT	Placebo mITT		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	120	117		
Units: Participants	68	25		

Statistical analyses

Statistical analysis title	SPL7013 Gel vs Placebo
Comparison groups	SPL7013 Gel mITT v Placebo mITT
Number of subjects included in analysis	237
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Secondary: Number of Women With Nugent Cure at the EOT Visit

End point title	Number of Women With Nugent Cure at the EOT Visit

End point description:

Nugent Cure is defined as a Nugent score of 0-3 (normal)

End point type	Secondary

End point timeframe:

Day 9-12

End point values	SPL7013 Gel mITT	Placebo mITT		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	120	117		
Units: Participants	16	6		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Women With Clinical Cure at the Test of Cure Visit (TOC)

End point title	Number of Women With Clinical Cure at the Test of Cure Visit (TOC)

End point description:

Clinical Cure is defined as the resolution of clinical findings (ie Amsel criteria) from the Baseline visit (Day 1)

End point type	Secondary

End point timeframe:

Day 21-30

End point values	SPL7013 Gel mITT	Placebo mITT		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	120	117		
Units: Participants	34	33		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Women With Nugent Cure at the TOC Visit

End point title	Number of Women With Nugent Cure at the TOC Visit

End point description:

Nugent Cure is defined as a Nugent score of 0-3 (normal)

End point type	Secondary

End point timeframe:

Day 21-30

End point values	SPL7013 Gel mITT	Placebo mITT		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	120	117		
Units: Participants	16	13		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information	
Timeframe for reporting adverse events: Screening/baseline through TOC visit, Day 1-30	
Adverse event reporting additional description: Number of participants experiencing adverse events.	
Assessment type	Non-systematic

Dictionary used	
Dictionary name	MedDRA
Dictionary version	14

Reporting groups	
Reporting group title	1% SPL7013 Gel
Reporting group description: -	
Reporting group title	Placebo
Reporting group description: -	

Serious adverse events	1% SPL7013 Gel	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 126 (0.00%)	0 / 123 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	1% SPL7013 Gel	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	15 / 126 (11.90%)	8 / 123 (6.50%)	
Nervous system disorders			
Headache			
subjects affected / exposed	15 / 126 (11.90%)	8 / 123 (6.50%)	
occurrences (all)	15	8	
Infections and infestations			
Vulvovaginal candidiasis			
subjects affected / exposed	11 / 126 (8.73%)	8 / 123 (6.50%)	
occurrences (all)	11	8	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

http://www.ncbi.nlm.nih.gov/pubmed/31812702